GlassScriptPhysician profile
Ishak G Soliman
NPI 1578505509
$12,195.95
in general payments reported to CMS, 2019-2025
50 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $1,569 · 2021: $1,970 · 2022: $1,786 · 2023: $2,169 · 2024: $1,587 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,903.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,188.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,236.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,159.76 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $679.33 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $641.02 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $493.12 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $469.78 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Lilly USA, LLC | $453.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $446.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $417.68 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.60 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $336.40 | 2020-2023 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $296.94 | 2021-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $276.52 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $261.91 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishak Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.